AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings or view top-rated stocks.

1 brokers have issued 12 month price targets for AcelRx Pharmaceuticals' stock. Their ACRX share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 763.6% from the stock's current price.
View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts.

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 74.4% and is now trading at $0.5790.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACRX earnings forecast.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings results on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.12. The specialty pharmaceutical company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.08 million. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 100.94%.

AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Values First Advisors Inc. (1.12%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela P Palmer and Vincent J Angotti.
View institutional ownership trends.

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRX stock can currently be purchased for approximately $0.58.

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $9.46 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or ($3.09) on an earnings per share basis.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.